FrancophonIA/ELRC3.0 huggingface dataset:
English: Overall Survival (OS): OS ranged from 29% to 87% with a follow-up ranging from 22 up to 63 months.
Slovenian: Celokupno preživetje: celokupno preživetje se giblje od 29 % do 87 % za obdobje med 22 in 63 meseci.
English: After reconstitution, each ml contains 10 mg thiotepa (10 mg/ml).
Slovenian: Po rekonstituciji en ml vsebuje 10 mg tiotepe (10 mg/ml).
English: Overall Survival: OS ranged from 30% to 87% with a follow-up ranging from 11.7 up to 87 months.
Slovenian: Celokupno preživetje: celokupno preživetje je bilo od 30 % do 87 % za obdobje med 11,7 in 87 meseci.
English: Infection susceptibility increased Sepsis
Slovenian: - povečana občutljivost za okužbo
English: Like all medicines, TEPADINA can cause side effects, although not everybody gets them.
Slovenian: Možni neželeni učinki Kot vsa zdravila ima lahko tudi zdravilo TEPADINA neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
English: Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being lower than 40% (which was considered by the physicians as the threshold to prove efficacy).
Slovenian: Ponovitev bolezni: pri vseh pripravljalnih zdravljenjih s tiotepo so poročali o stopnjah ponovitve v obdobju več kot enega leta v višini manj kot 40% (kar zdravniki označujejo kot prag za dokazovanje učinkovitosti).
English: Overall Survival: OS ranged from 31% to 81% with a follow-up ranging from 7.3 up to 120 months.
Slovenian: Celokupno preživetje: celokupno preživetje je bilo med 31 % in 81 % za obdobje med 7,3 in 120 meseci.
English: More generally, live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination.
Slovenian: Na splošno se živa virusna in bakterijska cepiva ne smejo uporabljati pri bolnikih, ki prejemajo zdravilo za zaviranje imunske odzivnosti.
English: Metabolism and nutrition disorders Anorexia Hyperglycaemia
Slovenian: Presnovne in prehranske motnje anoreksija hiperglikemija
English: Preparation of TEPADINA
Slovenian: Priprava zdravila TEPADINA
English: Delirium Nervousness Hallucination Agitation
Slovenian: Psihiatrične motnje stanje zmedenosti duševne motnje anksioznost delirij živčnost halucinacije vznemirjenost
English: Renal impairment The effects of renal impairment on thiotepa elimination have not been assessed.
Slovenian: Vpliv na odstranjevanje tiotepe pri motnjah v delovanju ledvic ni bil ocenjen.
English: TEPADINA is used to prepare patients for bone marrow transplantation.
Slovenian: Z zdravilom TEPADINA bolnike pripravljamo na presaditev kostnega mozga.
English: LYMPHOMA
Slovenian: LIMFOM
English: This leaflet was last revised in
Slovenian: Navodilo je bilo nazadnje revidirano dne: Drugi viri informacij
English: - TEPADINA does not contain any other ingredients.
Slovenian: - Zdravilo TEPADINA ne vsebuje pomožnih snovi.
English: TEPADINA is a white crystalline powder supplied in a glass vial containing 100 mg thiotepa.
Slovenian: Zdravilo TEPADINA je bel kristalinični prašek, na voljo v stekleni viali, ki vsebuje 100 mg tiotepe.
English: Daily white blood cell counts and platelet counts are recommended during therapy with thiotepa and after transplant for at least 30 days.
Slovenian: Med zdravljenjem s tiotepo in najmanj 30 dni po presaditvi je treba dnevno preverjati sliko belih krvnih celic in število trombocitov.
English: Thiotepa Read this guide prior to the preparation and administration of TEPADINA.
Slovenian: Tiotepa Pred pripravo in uporabo zdravila TEPADINA preberite to navodilo.
English: LYMPHOMA The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day
Slovenian: Priporočeni odmerek pri hematoloških boleznih je od 125 mg mg/m2 na dan (3,38 mg/kg/dan) do
English: Musculoskeletal and connective tissue disorders
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva zastoj rasti
English: Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being 60% or lower, which was considered by the physicians as the threshold to prove efficacy.
Slovenian: Ponovitev bolezni: pri vseh pripravljalnih zdravljenjih s tiotepo so poročali o stopnjah ponovitve po več kot enem letu v višini 60 % ali manj, kar zdravniki označujejo kot prag za dokazovanje učinkovitosti.
English: Liver failure
Slovenian: Ledvična okvara
English: If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water (see section
Slovenian: Če pride tiotepa nenamerno v stik s sluznico, sluznico temeljito sperite z vodo (glejte poglavje 6.6).
English: SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING
Slovenian: POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE IN RAVNANJE Z ZDRAVILOM
English: Headache Encephalopathy Convulsion Cerebral haemorrhage Memory impairment Paresis
Slovenian: Bolezni živčevja glavobol encefalopatija konvulzije možganska krvavitev motnje spomina pareza ataksija
English: TEPADINA is a white crystalline powder supplied in a glass vial containing 15 mg thiotepa.
Slovenian: Zdravilo TEPADINA je bel kristalinični prašek, na voljo v stekleni viali, ki vsebuje 15 mg tiotepe.
English: Linearity /non linearity There is no clear evidence of saturation of metabolic clearance mechanisms at high doses of thiotepa.
Slovenian: Ni jasnih dokazov o zasičenosti mehanizmov presnovnega očistka pri visokih odmerkih tiotepe.
English: • with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;
Slovenian: pred alogensko ali avtologno presaditvijo krvotvornih matičnih celic (PKMC) pri hematoloških boleznih pri odraslih in pediatričnih bolnikih;
English: Disease Free Survival (DFS): Percentages reported with follow-up periods of more than 1 year and up to 5 years confirm that conditioning treatments containing thiotepa following allogeneic HPCT are effective choices for treating patients with haematological diseases.
Slovenian: Preživetje brez ponovitve bolezni: Odstotki, o katerih so poročali v nadaljnjem obdobju več kot enega leta in do pet let potrjujejo, da so pripravljalna zdravljenja s tiotepo po alogenski PKMC učinkovita izbira za zdravljenje bolnikov s hematološkimi boleznimi.
English: It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect these functions.
Slovenian: Zelo verjetno je, da lahko nekateri neželeni učinki tiotepe, kot so omotica, glavobol in zamegljen vid,
English: Disease Free Survival (DFS): An estimated 43% at five years has been reported, confirming that conditioning treatments containing thiotepa following autologous HPCT are effective therapeutic strategies for treating patients with haematological diseases.
Slovenian: Preživetje brez ponovitve bolezni (DFS: Disease Free Survival): poročila navajajo ocenjenih 43 % pri petletnem preživetju brez ponovitve bolezni, kar potrjuje, da so pripravljalna zdravljenja s tiotepo po avtologni PKMC učinkovite terapevtske strategije za zdravljenje bolnikov s hematološkimi boleznimi.
English: Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being lower than 60%, which was considered by the physicians as the threshold to prove efficacy.
Slovenian: Ponovitev bolezni: pri vseh pripravljalnih zdravljenjih s tiotepo so poročali o stopnjah ponovitve v obdobju več kot enega leta v manj kot 60 %, kar zdravniki označujejo kot prag za dokazovanje učinkovitosti.
English: Acute graft versus host disease Chronic graft versus host disease
Slovenian: Bolezni imunskega sistema akutna reakcija presadka proti gostitelju kronična reakcija presadka proti gostitelju
English: CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to decreased concentrations of the active 4-OHCP.
Slovenian: CYP2B6 katalizira presnovno pretvorbo ciklofosfamida v njegovo aktivno obliko 4-hidroksi ciklofosfamid (4
English: Disease Free Survival (DFS): Percentages reported with follow-up periods of more than 1 year confirm that conditioning treatments containing thiotepa following autologous HPCT are effective choices for treating patients with solid tumours.
Slovenian: Preživetje brez ponovitve bolezni: odstotki, o katerih so poročali v nadaljnjem obdobju več kot enega leta, potrjujejo, da so pripravljalna zdravljenja s tiotepo po avtologni PKMC učinkovita izbira za zdravljenje bolnikov s čvrstimi tumorji.
English: TEPADINA must be reconstituted and diluted prior to administration.
Slovenian: Zdravilo TEPADINA je treba pred uporabo rekonstituirati in razredčiti.
English: Venoocclusive liver disease Hepatomegaly Jaundice
Slovenian: žolčnika in žolčevodov venookluzivna bolezen jeter hepatomegalija zlatenica
English: Chemical and physical in-use stability after reconstitution has been demonstrated for 8 hours when stored at 2°C-8°C.
Slovenian: Dokazano je bilo, da je rekonstituirana raztopina kemijsko in fizikalno stabilna 8 ur, če je bila hranjena pri 2 °C-8 °C.
English: The reconstituted solution is hypotonic and must be further diluted prior to administration with 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection (1000 ml if the dose is higher than 500 mg) or with an appropriate volume of sodium chloride 9 mg/ml (0.9%) in order to obtain a final TEPADINA concentration between 0.5 and 1 mg/ml.
Slovenian: 500 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje (če je predpisan odmerek večji od 500 mg, uporabite 1000 ml) ali z ustrezno količino natrijevega klorida 9 mg/ml (0,9 %), da dosežeto končno koncentracijo zdravila TEPADINA med 0.5 in 1 mg/ml.
English: One vial contains 15 mg thiotepa.
Slovenian: Ena viala vsebuje 15 mg tiotepe.
English: Solutions containing a precipitate should be discarded.
Slovenian: Raztopine, ki vsebujejo oborino, zavrzite.
English: Enteritis Intestinal obstruction
Slovenian: - limfatična obstrukcija
English: One vial contains 100 mg thiotepa.
Slovenian: Ena viala vsebuje 100 mg tiotepe.
English: - inflammation and exfoliation of the skin (erythrodermic psoriasis) - delirium, nervousness, hallucination, agitation - gastrointestinal ulcer - inflammation of the muscular tissue of the heart (myocarditis) - abnormal heart condition (cardiomyopathy)
Slovenian: - vnetje in luščenje kože (eritrodermična psoriaza) - delirij, živčnost, halucinacije, vznemirjenost
English: The total volume of reconstituted vials to be administered should be further diluted in 500 ml of sodium chloride 9 mg/ml (0.9%) solution for injection prior to administration (1000 ml if the dose is higher than 500 mg).
Slovenian: Skupno prostornino viale je treba pred injiciranjem nadalje razredčiti z dodajanjem 500 ml natrijevega klorida 9 mg/ml (0,9 %) (če je predpisan odmerek večji od 500 mg, uporabite 1000 ml).
English: Thiotepa has not been studied in patients with hepatic impairment.
Slovenian: Uporabe tiotepe pri bolnikih z okvaro jeter niso proučevali.
English: After dilution the product is stable for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C.
Slovenian: Po redčenju je zdravilo stabilno 24 ur, če je shranjeno pri temperaturi 2 °C-8 °C, in 4 ure, če je shranjeno pri 25 °C.
English: Stomatitis Oesophagitis Vomiting Diarrhoea Dyspepsia Abdominal pain Enteritis Colitis
Slovenian: Bolezni prebavil navzea stomatitis ezofagitis bruhanje driska dispepsija abdominalne bolečine enteritis kolitis zaprtost predrtje črevesja ileus razjeda prebavil
English: Haemorrhage
Slovenian: TALASEMIJA
English: Using a syringe fitted with a needle, aseptically withdraw 10 ml of sterile water for injections.
Slovenian: S pomočjo injekcijske brizge z iglo aseptično odvzemite 10 ml sterilne vode za injekcije.
English: Using a syringe fitted with a needle, aseptically withdraw 1.5 ml of sterile water for injection.
Slovenian: S pomočjo injekcijske brizge z iglo aseptično odvzemite 1,5 ml sterilne vode za injekcije.
English: Each TEPADINA vial must be reconstituted with 10 ml of sterile water for injection.
Slovenian: Vsako vialo TEPADINA je treba rekonstituirati z 10 ml sterilne vode za injiciranje.
English: Blood bilirubin increased Transaminases increased Blood creatinine increased Aspartate aminotransferase increased Alanine aminotransferase increased
Slovenian: Preiskave zvečane vrednosti bilirubina v krvi zvečana vrednost transaminaz zvečana vrednost kreatinina v krvi zvečana vrednost aspartataminotransferaze zvečana vrednost alaninaminotransferaze zvečane vrednosti sečnine v krvi nenormalne vrednosti elektrolitov v krvi zvečano razmerje protrombinskega časa
English: After reconstitution with 10 ml of water for injections, each ml of solution contains 10 mg thiotepa (10 mg/ml).
Slovenian: Po rekonstituciji z 10 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe (10 mg/ml).
English: One vial of powder contains 100 mg thiotepa.
Slovenian: Ena viala s praškom vsebuje 100 mg tiotepe.
English: After reconstitution with 1.5 ml of water for injections, each ml of solution contains 10 mg thiotepa (10 mg/ml).
Slovenian: Po rekonstituciji z 1,5 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe (10 mg/ml).
English: One vial of powder contains 15 mg thiotepa.
Slovenian: Ena viala s praškom vsebuje 15 mg tiotepe.
English: Erythema Desquamation Pigmentation disorder
Slovenian: Bolezni kože in podkožja izpuščaj eritem deskvamacija motnja pigmentacije
English: Pigmentation disorder Erythrodermic psoriasis
Slovenian: Bolezni kože in podkožja izpuščaj srbečica alopecija eritem motnja pigmentacije eritrodermična psoriaza
English: TRM values ranged from 0% to 21% at 1 year, confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with haematological diseases.
Slovenian: Vrednosti TRM so od 0 do 21 % za eno leto, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za avtologno PKMC pri odraslih bolnikih s hematološkimi boleznimi.
English: - anxiety, confusion - abnormal bulging outward of one of the arteries in the brain (intracranial aneurysm) - creatinine elevated - allergic reactions - occlusion of a blood vessel (embolism) - heart rhythm disorder - heart inability - cardiovascular inability - oxygen deficiency - fluid accumulation in the lungs (pulmonary oedema) - pulmonary bleeding - respiratory arrest - blood in the urine (haematuria) and moderate renal insufficiency - inflammation of the urinary bladder - discomfort in urination and decrease in urine output (disuria and oliguria) - increase in the amount of nitrogen components in the blood stream (BUN increase) - cataract - inability of the liver - cerebral haemorrhage - cough - constipation and upset stomach - obstruction of the bowel - perforation of stomach - changes in muscle tone - gross lack of coordination of muscle movements - bruises due to a low platelet count - menopausal symptoms - cancer (second primary malignancies) - abnormal brain function - male and female infertility
Slovenian: - kri v urinu (hematurija) in zmerna ledvična insuficienca - vnetje sečnega mehurja - bolečine pri uriniranju in manjša količina izločenega urina (dizurija in oligurija) - večja količina dušikovih sestavin v krvi (zvišanje dušika sečnine v krvi - BUN)
English: If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water.
Slovenian: Če pride tiotepa nenamerno v stik s sluznico, sluznico temeljito sperite z vodo.
English: Each TEPADINA vial must be reconstituted with 1.5 ml of sterile water for injection.
Slovenian: Vsako vialo TEPADINA je treba rekonstituirati z 1,5 ml sterilne vode za injiciranje.
English: Accord Healthcare B.V. Tel: +31 30 850 6014
Slovenian: Tel: +31 30 850 6014
English: Leukopenia Thrombocytopenia Febrile neutropenia Anaemia
Slovenian: Bolezni krvi in limfatičnega sistema levkopenija trombocitopenija febrilna nevtropenija anemija pancitopenija granulocitopenija
English: TEPADINA is supplied as 100 mg powder for concentrate for solution for infusion.
Slovenian: Zdravilo TEPADINA je na voljo kot 100 mg prašek za koncentrat za raztopino za infundiranje.
English: Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2°C -8°C and for 4 hours when stored at 25°C.
Slovenian: Dokazano je bilo, da je po redčenju raztopina kemijsko in fizikalno stabilna 24 ur, če je bila hranjena pri 2 °C -8 °C in 4 ure, če je bila hranjena pri 25 °C.
English: Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2°C-8°C and for 4 hours when stored at 25°C.
Slovenian: Dokazano je bilo, da je po redčenju raztopina kemijsko in fizikalno stabilna 24 ur, če je bila hranjena pri 2 °C-8 °C, in 4 ure, če je bila hranjena pri 25 °C.
English: Live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination.
Slovenian: Posebne interakcije s tiotepo Živa virusna in bakterijska cepiva se ne smejo uporabljati pri bolnikih, ki prejemajo zdravilo za zaviranje imunske odzivnosti.
English: TEPADINA is supplied as 15 mg powder for concentrate for solution for infusion.
Slovenian: Zdravilo TEPADINA je na voljo kot 15 mg prašek za koncentrat za raztopino za infundiranje.
English: The recommended dose in haematological diseases ranges from 185 mg/m2/day (5 mg/kg/day) to 481 mg/m2/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment.
Slovenian: Priporočeni odmerek pri hematoloških boleznih je od 185 mg/m2 na dan (5 mg/kg/dan) do 481 mg/m2 na dan (13 mg/kg/dan), razdeljen na eno ali dve infuziji na dan, in se daje 1 do 3 zaporedne dni pred alogensko PKMC, odvisno od kombinacije z drugimi kemoterapevtiki, ne da bi se presegel skupni največji kumulativni odmerek 555 mg/m2 (15 mg/kg) v času celotnega pripravljalnega zdravljenja.
English: The recommended dose is 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered in 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 500 mg/m2 (13.51 mg/kg), during the time of the entire conditioning treatment.
Slovenian: Priporočeni odmerek je 250 mg/m2/dan (6,76 mg/kg/dan) v obliki ene infuzije na dan, ki se daje dva zaporedna dneva pred avtologno PKMC, ne da bi se presegel skupni največji kumulativni odmerek 500 mg/m2 (13,51 mg/kg) v času celotnega pripravljalnega zdravljenja.
English: After reconstitution with 1.5 ml of water for injection, each ml contains 10 mg thiotepa.
Slovenian: Po rekonstituciji z 1,5 ml vode za injekcije en ml raztopine vsebuje 10 mg tiotepe.
English: Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 0% to 26.7% have been reported.
Slovenian: Z režimom povezana umrljivost in s presaditvijo povezana umrljivost: poročali so o vrednostih RRM med 0 in 26,7 %.
English: Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values ranging from 2.5% to 29% have been reported.
Slovenian: Z režimom povezana umrljivost (RRM: Regimen Related Mortality) in s presaditvijo povezana umrljivost (TRM: Transplant related Mortality): poročali so o vrednostih RRM od 2,5 do 29 odstotkov.
English: In some of the conditioning treatments evaluated, relapse rates lower than 60% have also been reported at 5 years.
Slovenian: Pri nekaterih ocenjenih pripravljalnih zdravljenjih so poročali tudi o stopnjah ponovitve,
English: TEPADINA 15 mg powder for concentrate for solution for infusion
Slovenian: TEPADINA 15 mg prašek za koncentrat za raztopino za infundiranje
English: TRM values ranged from 0% to 7.4% confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with solid tumours.
Slovenian: Vrednosti TRM so od 0 do 7,4 odstotkov, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za avtologno PKMC pri odraslih bolnikih s čvrstimi tumorji.
English: This leaflet was last revised in:
Slovenian: Pogostnost je opredeljena kot sledi:
English: The recommended dose ranges from 200 mg/m2/day (8 mg/kg/day) to 250 mg/m2/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment.
Slovenian: Priporočeni odmerek je od 200 mg/m2 na dan (8 mg/kg/dan) do 250 mg/m2 na dan (10 mg/kg/dan), razdeljen na dve infuziji na dan pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 250 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja.
English: TRM values ranged from 0% to 30% confirming the safety of the conditioning treatment including thiotepa for allogeneic HPCT in paediatric patients with haematological diseases.
Slovenian: Vrednosti TRM so bile med 0 in 30 %, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za alogensko PKMC pri pediatričnih bolnikih s hematološkimi boleznimi.
English: TEPADINA can impair male and female fertility.
Slovenian: Zdravilo TEPADINA lahko zmanjša plodnost moških in žensk.
English: TEPADINA 100 mg powder for concentrate for solution for infusion
Slovenian: TEPADINA 100 mg prašek za koncentrat za raztopino za infundiranje
English: Frequencies are defined as: very common (≥1/10), common ((≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) very rare (<1/10,000), not known (cannot be estimated from the available data).
Slovenian: < 1/1.000), zelo redki (< 1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: TRM values ranged from 0% to 18% confirming the safety of the conditioning treatments including thiotepa for autologous HPCT in paediatric patients with solid tumours.
Slovenian: Vrednosti TRM so bile med 0 in 18 %, kar potrjuje varnost pripravljalnega zdravljenja s tiotepo za avtologno PKMC pri pediatričnih bolnikih s čvrstimi tumorji.
English: Hearing impaired Ototoxicity Tinnitus
Slovenian: vključno z motnjami labirinta motnje sluha ototoksičnost tinitus
English: Idiopathic pneumonia syndrome Pulmunary haemorrage Pulmonary oedema
Slovenian: Bolezni dihal, prsnega koša in mediastinalnega prostora pljučnica sindrom idiopatske pnevmonije pljučna krvavitev pljučni edem epistaksa hipoksija zastoj dihanja
English: The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment.
Slovenian: REFRAKTARNA CITOPENIJA Priporočeni odmerek je 125 mg/m2/dan (5 mg/kg/dan) v obliki ene infuzije na dan, ki se daje tri zaporedne dni pred alogensko PKMC, ne da bi se presegel skupni največji kumulativni odmerek 375 mg/m2 (15 mg/kg) v času celotnega pripravljalnega zdravljenja.
English: Allogeneic HPCT
Slovenian: ALOGENSKA PKMC
English: ALLOGENEIC HPCT
Slovenian: Alogenska PKMC
English: Dysuria Oliguria Renal failure Cystitis Haematuria
Slovenian: Bolezni sečil hemoragični cistitis dizurija oligurija odpoved ledvic cistitis hematurija
English: CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2 (10 mg/kg), during the time of the entire conditioning treatment.
Slovenian: LIMFOM V OSREDNJEM ŽIVČEVJU Priporočeni odmerek je 185 mg/m2 na dan (5 mg/kg/dan) v obliki ene infuzije na dan in se daje dva zaporedna dneva pred avtologno PKMC, ne da bi se presegel skupni največji kumulativni odmerek 370 mg/m2 (10 mg/kg) v času celotnega pripravljalnega zdravljenja